Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Glenmark

- PMLiVE

Gilead builds case for Descovy PrEP after FDA approval

Reported statistically significant improvements in kidney function

- PMLiVE

Gilead claims FDA okay for Descovy as second PrEP option

Can now push new indication before generics dent franchise

- PMLiVE

Arbutus hit hard as new hep B drug fails on safety

Shares have fallen sharply since company reported results

- PMLiVE

Gilead continues its exec clear-out, licenses antivirals from Novartis

Long-standing R&D chief to depart

- PMLiVE

Gilead strikes $5.1bn deal to bolster ties with Galapagos

Big boost for Belgian biotech, without a buy-out

- PMLiVE

25 Women Leaders in UK Healthcare (part 2)

25 Women in UK healthcare, Part 2   (Click here for Part 1)13. SORAYA BEKKALI Gene therapy pioneerCell and gene therapy is definitely the most exciting development in biopharma research, promising...

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

- PMLiVE

Gilead’s NASH drug fails again

Drug failed to match results from placebo group

- PMLiVE

Gilead drives NASH development with insitro collaboration

Announcement comes days after Novo Nordisk deal

- PMLiVE

Gilead and Galapagos close in on filing for Xeljanz rival

Belgian biotech gearing up for first approval

- PMLiVE

Riva leaves Gilead to head Glenmark’s innovation spin-off

Company has own bispecific antibody platform

- PMLiVE

Gilead lead NASH drug flunks phase 3 test

Analysts suspect the setback could prompt Gilead to license other candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links